Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Novel antibodies in AML

Marion Subklewe • 26 Aug 2020
SOHO 2020
Acute Myeloid Leukemia Leukemia Antibodies Azacitidine Gemtuzumab ozogamicin Lintuzumab-Ac225 Nivolumab

Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, outlines novel antibody-based immunotherapies developed for the treatment of acute myeloid leukemia (AML), as well as challenges with implementing these agents. Prof. Subklewe also discusses the development of gemtuzumab, the only antibody-drug conjugate approved for the treatment of AML as well as checkpoint inhibitors such as nivolumab, that have been investigated in monotherapy and combination in this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Marion Subklewe

AVC-201: a CAR-T using a switchable module in AML
13:39
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe • 19 Sep 2026
Emerging immunotherapy strategies in AML: CAR-T, NK cells and T-cell engagers
17:01
Emerging immunotherapy strategies in AML: CAR-T, NK cells and T-cell engagers
David Sallman et al. • 20 Sep 2026
The GoCART Observership Programme: promoting knowledge transfer & building a European CAR-T network
1:46
The GoCART Observership Programme: promoting knowledge transfer & building a European CAR-T network
Marion Subklewe • 24 Mar 2026
Factors contributing to the reduction in the incidence of higher-grade CRS and ICANS
4:06
Factors contributing to the reduction in the incidence of higher-grade CRS and ICANS
Marion Subklewe • 24 Mar 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals